Chief
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Japan
I am a medical oncologist and chief of Department of Head and Neck, and Esophageal Medical Oncology, and Gastrointestinal Medical Oncology, National Cancer Center Hospital, 2020-2022, and chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office, National Cancer Center Hospital. My primary interest is chemotherapy and chemoradiotherapy for oesophageal, esophagogastric, and gastric cancer. I am a group coordinator of the Japan Esophageal Oncology Group of JCOG, the most significant clinical trial group for cancer in Japan.
Our group has conducted clinical trials to develop new chemotherapy for metastatic disease and early oesophageal cancer in multimodality therapy. As a study coordinator, I conducted the randomized phase III trial, which compared the surgery and chemoradiotherapy for clinical stage I oesophageal squamous carcinoma, named JCOG0502, which reported the non-inferiority of chemoradiotherapy to surgery. The randomized phase III trial of neoadjuvant therapy for resectable oesophageal squamous cell carcinoma, named JCOG1109, showed superior survival of triplet-chemotherapy over doublet-chemotherapy. This trial gave a new aspect to neoadjuvant therapy for esophageal cancer.
To develop new drugs, such as immune-checkpoint inhibitors, I committed to the international phase III trial of oesophageal cancer as a steering committee member, for example, ATTRACTION-3 KEYNOTE-590, CheckMate-649, RATIONALE-306, and others.
